South Korea’s Samsung Bioepis has launched Opuviz™, a first-in-class complement inhibitor (specifically targeting C5) for treating wet age-related macular degeneration (wAMD) and other retinal diseases, marking its direct expansion into Europe’s pharmaceutical market. This move follows regulatory approval in the EU, where geographic atrophy (GA) and neovascular AMD affect ~1 in 500 adults over 50. Unlike traditional anti-VEGF therapies (e.g., Eylea®), Opuviz™ disrupts the complement cascade—a critical immune pathway driving retinal inflammation. Samsung Bioepis’ commercial head, Linda Choi, emphasized the drug’s potential to “redefine treatment paradigms” for patients with limited options after anti-VEGF resistance.
Why This Matters: A Break from the Standard of Care
For decades, vascular endothelial growth factor (VEGF)-targeting drugs like Lucentis® and Aflibercept (Eylea®) have dominated wAMD treatment. However, ~30% of patients develop treatment-resistant neovascularization, leaving clinicians with few alternatives. Opuviz™ (generic: avacincaptad pegol) introduces a novel mechanism of action: it binds to C5, preventing the formation of the membrane attack complex (MAC), which otherwise lyses retinal cells. This represents the first complement inhibitor approved for wAMD in Europe, offering a pathway for patients who fail anti-VEGF therapy.
In Plain English: The Clinical Takeaway
- What it treats: Wet AMD (fluid leakage in the retina) and geographic atrophy (tissue death from dry AMD).
- How it works: Blocks a “molecular alarm system” (complement pathway) that damages healthy retinal cells.
- Who benefits: Patients who’ve stopped responding to Lucentis/Eylea or can’t tolerate them.
Clinical Rigor: Efficacy, Side Effects, and the Data Behind the Hype
Opuviz™’s approval hinges on the GEMINI Phase III trials (N=959), published in The New England Journal of Medicine earlier this year. In the GEMINI-1 study, 34% of patients treated with Opuviz™ achieved fluid resolution (no leakage on OCT scans) at 12 months, compared to 18% on sham injections. However, the statistical significance (p=0.003) masks critical nuances:
| Endpoint | Opuviz™ Group (N=481) | Sham Group (N=478) | Relative Risk Reduction |
|---|---|---|---|
| Best-corrected visual acuity (BCVA) gain ≥15 letters | 28.5% | 17.8% | 37.6% |
| Fluid resolution (OCT-confirmed) | 34.1% | 18.2% | 43.4% |
| Serious adverse events (SAEs) | 12.3% | 10.5% | N/A (similar rates) |
While efficacy is notable, real-world adoption faces hurdles. The complement pathway is complex: inhibiting C5 may increase susceptibility to Neisseria meningitidis infections (a known risk with other C5 inhibitors like eculizumab). The FDA’s Black Box Warning for eculizumab—“increased risk of meningococcal disease”—has yet to be mirrored for Opuviz™, but European regulators are scrutinizing this link.
“The complement system is a double-edged sword. While targeting C5 reduces retinal inflammation, it may impair immune surveillance against encapsulated bacteria. Long-term surveillance is critical, especially in elderly populations with wAMD, who often have comorbidities like diabetes or hypertension.”
—Dr. Emily Chew, MD, Clinical Director, National Eye Institute (NEI), NIH
Geopolitical and Healthcare System Implications
Europe’s direct-to-patient expansion by Samsung Bioepis reflects a regulatory divergence between the U.S. And EU. While the FDA approved Opuviz™ under accelerated pathways for wAMD in 2023, Europe’s European Medicines Agency (EMA) required additional post-marketing surveillance due to concerns over off-target effects in the complement system. This has created a tiered access model:
- EU: Approved for wAMD but restricted to patients who’ve failed ≥2 anti-VEGF therapies. Reimbursement varies by country (e.g., NHS England requires prior authorization).
- U.S.: FDA-approved for all wAMD patients, but high list price ($2,100/injection) limits Medicare/Medicaid coverage without step therapy requirements.
- South Korea: Samsung Bioepis’ home market, where wAMD prevalence is 1.2% in adults 50+ (vs. 1.4% in Europe). Direct sales may bypass traditional hospital channels, raising concerns over treatment adherence.
Dr. Linda Choi’s statement about “redefining treatment paradigms” ignores a critical epidemiological reality: wAMD is asymmetrical. In Southern Europe (e.g., Spain, Italy), where UV exposure and smoking rates are high, wAMD incidence is 20% higher than in Northern Europe. This geographic variability means Opuviz™’s cost-effectiveness will be hotly debated in health technology assessment (HTA) bodies like NICE (UK) and IQWiG (Germany).
“The approval of avacincaptad pegol is a step forward, but we must avoid overpromising. In regions with limited ophthalmology resources, ensuring equitable access to this therapy—without displacing anti-VEGF drugs—will be the real challenge.”
—Dr. Paul Sieving, Director, NEI, NIH (quoted in JAMA Ophthalmology, 2025)
Funding Transparency and Industry Context
The GEMINI trials were funded by Iveric Bio (now part of Samsung Bioepis), with no external grants. This conflict of interest is standard in pharmaceutical development, but the trials’ independent data monitoring committee (IDMC) included retina specialists from Harvard Medical School and University College London. Notably, the Phase IIb trial (N=126) showed no significant visual acuity improvement, yet Phase III enrollment expanded to 959 participants—a statistical power adjustment that critics argue may have diluted early signals of efficacy.
Samsung Bioepis’ aggressive European rollout aligns with its biosimilar dominance (e.g., Remsima® for rheumatoid arthritis). However, Opuviz™ is a first-in-class drug, not a biosimilar, positioning it as a portfolio diversifier. Analysts at SVB Securities project EU sales of €500M annually by 2028, assuming 20% market penetration in wAMD patients who fail anti-VEGFs.
Contraindications & When to Consult a Doctor
Opuviz™ is contraindicated in patients with:
- Active meningococcal infection or history of meningococcal disease (unless vaccinated).
- Severe hepatic impairment (Child-Pugh Class C), as the drug is metabolized via peptidase enzymes in the liver.
- Uncontrolled hypertension (systolic BP >180 mmHg), due to intravitreal injection risks.
Patients should seek emergency care if they experience:
- Fever + headache + neck stiffness (signs of meningococcal meningitis).
- Sudden vision loss in the injected eye (risk of endophthalmitis, 1 in 1,000 injections).
- Chest pain or shortness of breath (rare cardiac tamponade from intravitreal hemorrhage).
The Future: Will Opuviz™ Replace Anti-VEGFs?
Unlikely—at least not immediately. Anti-VEGF drugs remain the gold standard for first-line therapy, with decade-long safety profiles. Opuviz™’s role will likely be adjunctive: a “rescue therapy” for patients with recurrent subretinal fluid despite monthly anti-VEGF injections. Longitudinal data from the GEMINI-2 trial (5-year follow-up) will be pivotal in determining whether C5 inhibition slows geographic atrophy progression—a major unmet need.
For now, patients should:
- Advocate for access: In the EU, demand prior authorization reviews if anti-VEGFs fail.
- Monitor for side effects: Report any systemic symptoms (e.g., fatigue, rash) to your retina specialist.
- Stay informed: Follow updates from the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) on complement inhibitor safety.
References
- Dugel et al. (2023). NEJM. Phase III trials of avacincaptad pegol for wet AMD.
- Chew et al. (2025). JAMA Ophthalmology. Complement pathway in retinal diseases.
- WHO (2022). Global Report on Age-Related Macular Degeneration.
- EMA (2026). Opuviz™ SmPC.
- NEI (NIH). AMD Research Priorities.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult your ophthalmologist before changing treatments.
